Learn more about our international medical advisor and Paediatric ITP specialist, Michele Lambert as she shares a little about why she’s so passionate about paediatric ITP.
We wanted to get to know each of our ITP Australia Medical Advisory Board members a little more so we caught up with Terry recently to find out a little more about her and why she does the amazing things that she does.
At around this time each year in Australia, many ITP patients ask their primary care professional, whether it’s their GP or haematologist if they should be getting the annual influenza vaccine and there are always varying responses.
Dr Robert Bird, member of our Medical Advisory Board, has shared information about ITP patients being at an increased risk of blood clots and not just bleeding.
Welcome to the second edition of The Count.
In this edition, we have an update on the recently updated and published International Consensus Report for the diagnosis and management of ITP, an update of emerging treatments showcased at the 2019 American Society of Hematology Conference in Orlando Florida, details on the Local Patient Meetings, plus some information around blood clots and ITP Patients.
Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases. A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans.
On 30 January 2020, the WHO Director-General declared the novel coronavirus (2019-nCoV) outbreak a public health emergency of international concern.
Included in the following article is the recently published and updated International Consensus Report for the investigation, treatment and management of Immune Thrombocytopenia (ITP) in all patients.
Getting to know each and every one of the ITP Australia Medical Advisory Board members has been a lot of fun over the last couple of months. In this edition, we learn about one of our Australian ITP specialists, Rob Bird.
Through the ITP World Impact Survey (I-WISh), which was a collaborative global survey completed by over 1,400 ITP patients and 480 health professionals, we review the perceptions between physicians and patients and identify that fatigue is under-recognised as a symptom and its impact on a patients Quality of life (QoL).
The ITP Impact Survey (I-WISh) is a collaborative investigation among global ITP experts, patient support groups and Novartis Pharmaceuticals Corporation.
The mission of ITP Australia is supporting ITP patients and carers through information and support networks. Over the next 12 months we will be adding some new and expanded initiatives to offer even more to our ITP warriors.